| Not Yet Recruiting | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease NCT07536061 | Sarepta Therapeutics, Inc. | Phase 1 |
| Recruiting | iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009 NCT06634628 | CHDI Foundation, Inc. | EARLY_Phase 1 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's NCT07246941 | Hoffmann-La Roche | Phase 1 |
| Recruiting | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease NCT06585449 | Alnylam Pharmaceuticals | Phase 1 |
| Terminated | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease NCT05655520 | Supernus Pharmaceuticals, Inc. | Phase 3 |
| Completed | A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD NCT05107128 | Supernus Pharmaceuticals, Inc. | Phase 2 |
| Completed | HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States NCT03628235 | CHDI Foundation, Inc. | — |
| Active Not Recruiting | Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease NCT04120493 | UniQure Biopharma B.V. | Phase 1 / Phase 2 |
| Completed | Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or NCT03664804 | Hoffmann-La Roche | Phase 1 |
| Unknown | A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) NCT02509793 | William Ondo, MD | Phase 4 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139 NCT03342053 | Hoffmann-La Roche | Phase 2 |
| Completed | Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People NCT03306888 | Teachers College, Columbia University | Phase 1 / Phase 2 |
| Terminated | Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease NCT03225846 | Wave Life Sciences Ltd. | Phase 1 / Phase 2 |
| Terminated | Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease NCT03225833 | Wave Life Sciences Ltd. | Phase 1 / Phase 2 |
| Completed | FuRST 2.0 Cognitive Pre-Testing NCT02881931 | CHDI Foundation, Inc. | — |
| Completed | Exploring Computerised Cognitive Training for People With Huntington's Disease NCT02990676 | Cardiff University | N/A |
| Recruiting | HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Hu NCT02855476 | University College, London | — |
| Unknown | PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease NCT02263430 | Beijing Pins Medical Co., Ltd | N/A |
| Completed | Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases. NCT02750982 | Brown, Theodore R., M.D., MPH | N/A |
| Completed | Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease NCT02507284 | Azevan Pharmaceuticals | Phase 2 |
| Unknown | Functional Imaging of Social Cognition in Premanifest Huntington's Disease NCT02551705 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Terminated | A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease NCT02494778 | Prilenia | Phase 2 |
| Completed | Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers NCT02956148 | CHDI Foundation, Inc. | EARLY_Phase 1 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifes NCT02519036 | Ionis Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Effica NCT02481674 | Vaccinex Inc. | Phase 2 |
| Active Not Recruiting | ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders NCT02252380 | InSightec | N/A |
| Completed | Electronic-health Application To Measure Outcomes REmotely Clinical Trial NCT02418546 | Massachusetts General Hospital | N/A |
| Terminated | Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjec NCT02342548 | Pfizer | Phase 2 |
| Completed | Working Memory Training in Huntington's Disease NCT02926820 | York University | N/A |
| Completed | Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging NCT02550275 | University Hospital, Angers | N/A |
| Completed | A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Do NCT02215616 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Completed | Brain Stimulation in Movement Disorders NCT02216474 | Birmingham and Solihull Mental Health NHS Foundation Trust | N/A |
| Completed | Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Vo NCT02208934 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Phase 1 |
| Completed | Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's D NCT02197130 | Pfizer | Phase 2 |
| Terminated | Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients NCT02231580 | Ipsen | Phase 2 |
| Completed | A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patien NCT02006472 | Prilenia | Phase 2 |
| Terminated | Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease NCT02074410 | Omeros Corporation | Phase 2 |
| Completed | Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early H NCT01806896 | Pfizer | Phase 2 |
| Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurolo NCT01931644 | Sanguine Biosciences | — |
| Completed | [PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls NCT02061722 | CHDI Foundation, Inc. | EARLY_Phase 1 |
| Recruiting | Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort NCT01574053 | CHDI Foundation, Inc. | — |
| Completed | Apathy Cure Through Bupropion in Huntington's Disease NCT01914965 | Charite University, Berlin, Germany | Phase 2 |
| Completed | Exercise Effects in Huntington's Disease NCT01879267 | University of Zurich | N/A |
| Completed | A Phase II Safety and Tolerability Study With SEN0014196 NCT01521585 | Siena Biotech S.p.A. | Phase 2 |
| Completed | A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery NCT01592552 | Sanguine Biosciences | — |
| Completed | A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease NCT01485965 | Siena Biotech S.p.A. | Phase 1 |
| Completed | Neuroprotection by Cannabinoids in Huntington's Disease NCT01502046 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Phase 2 |
| Completed | Cognitive Assessment Battery (CAB) Beta Study NCT01290861 | CHDI Foundation, Inc. | — |
| Unknown | Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) NCT02101957 | University Hospital, Angers | Phase 2 / Phase 3 |
| Completed | Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability NCT01411163 | Massachusetts General Hospital | Phase 2 |
| Completed | Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease NCT01451463 | Ohio State University | — |
| Completed | Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) NCT00920699 | Johns Hopkins University | Phase 2 |
| Terminated | Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea NCT01019473 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Escalating Dose Study in Healthy Volunteers With SEN0014196 NCT01521832 | Siena Biotech S.p.A. | Phase 1 |
| Completed | A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin NCT00990613 | Pfizer | Phase 1 |
| Completed | A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational NCT00975481 | Pfizer | Phase 1 |
| Terminated | Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) NCT00712426 | Massachusetts General Hospital | Phase 3 |
| Completed | A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In He NCT00931073 | Pfizer | Phase 1 |
| Completed | Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study NCT01411150 | Massachusetts General Hospital | Phase 2 |
| Withdrawn | Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon NCT00907595 | Massachusetts General Hospital | N/A |
| Completed | Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease NCT00902889 | Heinrich-Heine University, Duesseldorf | Phase 1 |
| Completed | A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanes NCT00825084 | Pfizer | Phase 1 |
| Completed | A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF NCT00827034 | Pfizer | Phase 1 |
| Completed | A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerab NCT00824590 | Pfizer | Phase 1 |
| Completed | The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease NCT01735981 | Anne Kloos | N/A |
| Completed | A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease NCT00665223 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Terminated | Coenzyme Q10 in Huntington's Disease (HD) NCT00608881 | Massachusetts General Hospital | Phase 3 |
| Completed | A Study of the Novel Drug Dimebon in Patients With Huntington's Disease NCT00497159 | Medivation, Inc. | Phase 2 |
| Completed | Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD NCT00491842 | National Human Genome Research Institute (NHGRI) | — |
| Completed | Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease NCT00387270 | Medivation, Inc. | Phase 1 / Phase 2 |
| Completed | Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease NCT00670709 | University of California, Los Angeles | — |
| Completed | Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD) NCT00212316 | University of Rochester | Phase 2 |
| Recruiting | Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease NCT01860339 | Peggy C Nopoulos | — |
| Completed | Study of Memantine to Treat Huntington's Disease NCT00652457 | Jody Corey-Bloom, MD, PhD | Phase 4 |
| Completed | Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease NCT00095355 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |
| Completed | Effects of Music Therapy on Huntington's Disease NCT00178360 | University of Rochester | Phase 1 |
| Completed | REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) NCT01590589 | European Huntington's Disease Network | — |
| Completed | Creatine Therapy for Huntington's Disease NCT00026988 | National Center for Complementary and Integrative Health (NCCIH) | Phase 1 / Phase 2 |
| Completed | Minocycline in Patients With Huntington's Disease NCT00029874 | FDA Office of Orphan Products Development | Phase 1 / Phase 2 |
| Completed | Treatment of Huntington's Chorea With Amantadine NCT00001930 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |
| Completed | Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease NCT00004753 | National Center for Research Resources (NCRR) | — |
| Completed | Efficacy and Safety of Tetrabenazine in Chorea NCT00219804 | Prestwick Pharmaceuticals | Phase 3 |